REFERENCES
1. Evans MA, Walsh K. Clonal hematopoiesis, somatic mosaicism, and age-associated disease. Physiol Rev 2023;103:649-716.
3. Loh PR, Genovese G, Handsaker RE, et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature 2018;559:350-5.
4. Zekavat SM, Lin SH, Bick AG, et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med 2021;27:1012-24.
5. Dumanski JP, Halvardson J, Davies H, et al. Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. Cell Mol Life Sci 2021;78:4019-33.
6. Polizio AH, Park E, Walsh K. Clonal hematopoiesis: connecting aging and inflammation in atherosclerosis. Curr Atheroscler Rep 2023;25:105-11.
7. Sano S, Horitani K, Ogawa H, et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science 2022;377:292-7.
8. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-98.
9. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371:2477-87.
10. Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv 2018;2:3404-10.
11. Evans MA, Sano S, Walsh K. Clonal haematopoiesis and cardiovascular disease: how low can you go? Eur Heart J 2021;42:266-8.
12. Assmus B, Cremer S, Kirschbaum K, et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J 2021;42:257-65.
13. Sikking MA, Stroeks SLVM, Henkens MTHM, et al. Clonal hematopoiesis has prognostic value in dilated cardiomyopathy independent of age and clone size. JACC Heart Fail 2023;S2213:1779(23)00509.
14. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015;126:9-16.
15. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014;20:1472-8.
16. Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 2017;130:742-52.
17. Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell 2018;22:157-70.
18. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017;377:111-21.
19. Cremer S, Kirschbaum K, Berkowitsch A, et al. Multiple somatic mutations for clonal hematopoiesis are associated with increased mortality in patients with chronic heart failure. Circ Genom Precis Med 2020;13:e003003.
20. Honigberg MC, Zekavat SM, Niroula A, et al. Premature menopause, clonal hematopoiesis, and coronary artery disease in postmenopausal women. Circulation 2021;143:410-23.
21. Yu B, Roberts MB, Raffield LM, et al. Supplemental association of clonal hematopoiesis with incident heart failure. J Am Coll Cardiol 2021;78:42-52.
22. Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol 2019;4:25-33.
23. Pascual-Figal DA, Bayes-Genis A, Díez-Díez M, et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J Am Coll Cardiol 2021;77:1747-59.
24. Zekavat SM, Viana-Huete V, Matesanz N, et al. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. Nat Cardiovasc Res 2023;2:144-58.
25. Bhattacharya R, Zekavat SM, Haessler J, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke 2022;53:788-97.
26. Kar SP, Quiros PM, Gu M, et al. Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nat Genet 2022;54:1155-66.
27. Kessler MD, Damask A, O’Keeffe S, et al. Common and rare variant associations with clonal haematopoiesis phenotypes. Nature 2022;612:301-9.
28. Mas-Peiro S, Pergola G, Berkowitsch A, et al. Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR. Clin Res Cardiol 2023;112:585-93.
29. Gumuser ED, Schuermans A, Cho SMJ, et al. Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol 2023;81:1996-2009.
30. Cochran JD, Yura Y, Thel MC, et al. Clonal hematopoiesis in clinical and experimental heart failure with preserved ejection fraction. Circulation 2023;148:1165-78.
31. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017;355:842-7.
32. Sano S, Oshima K, Wang Y, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J Am Coll Cardiol 2018;71:875-86.
33. Wang Y, Sano S, Yura Y, et al. Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction. JCI Insight 2020;5:135204.
34. Yura Y, Miura-Yura E, Katanasaka Y, et al. The cancer therapy-related clonal hematopoiesis driver gene ppm1d promotes inflammation and non-ischemic heart failure in mice. Circ Res 2021;129:684-98.
35. Sano S, Wang Y, Ogawa H, et al. TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight 2021;6:e146076.
36. Buscarlet M, Provost S, Zada YF, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 2017;130:753-62.
37. Miller PG, Qiao D, Rojas-Quintero J, et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood 2022;139:357-68.
38. Dawoud AAZ, Gilbert RD, Tapper WJ, Cross NCP. Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia 2022;36:507-15.
39. Vlasschaert C, McNaughton AJM, Chong M, et al. Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol 2022;33:985-95.
40. Pasupuleti SK, Ramdas B, Burns SS, et al. Obesity-induced inflammation exacerbates clonal hematopoiesis. J Clin Invest 2023;133:e163968.
41. Wong WJ, Emdin C, Bick AG, et al. Clonal haematopoiesis and risk of chronic liver disease. Nature 2023;616:747-54.
42. Kim PG, Niroula A, Shkolnik V, et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med 2021;218:e20211872.
43. Agrawal M, Niroula A, Cunin P, et al. TET2-mutant clonal hematopoiesis and risk of gout. Blood 2022;140:1094-103.
44. Bolton KL, Koh Y, Foote MB, et al. Clonal hematopoiesis is associated with risk of severe Covid-19. Nat Commun 2021;12:5975.
45. Bick AG, Popadin K, Thorball CW, et al. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Sci Rep 2022;12:577.
46. Dharan NJ, Yeh P, Bloch M, et al. HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. Nat Med 2021;27:1006-11.
47. Hecker JS, Hartmann L, Rivière J, et al. CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. Blood 2021;138:1727-32.
48. Zhang CRC, Nix D, Gregory M, et al. Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients. Exp Hematol 2019;80:36-41.e3.
49. Cumbo C, Tarantini F, Zagaria A, et al. Clonal hematopoiesis at the crossroads of inflammatory bowel diseases and hematological malignancies: a biological link? Front Oncol 2022;12:873896.
50. Nachun D, Lu AT, Bick AG, et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell 2021;20:e13366.
51. Robertson NA, Hillary RF, McCartney DL, et al. Age-related clonal haemopoiesis is associated with increased epigenetic age. Curr Biol 2019;29:R786-7.
52. Kleppe M, Comen E, Wen HY, et al. Somatic mutations in leukocytes infiltrating primary breast cancers. NPJ Breast Cancer 2015;1:15005.
53. Hong W, Li A, Liu Y, et al. Clonal hematopoiesis mutations in patients with lung cancer are associated with lung cancer risk factors. Cancer Res 2022;82:199-209.
54. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun 2016;7:12484.
55. Robertson NA, Latorre-Crespo E, Terradas-Terradas M, et al. Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects. Nat Med 2022;28:1439-46.
56. Uddin MM, Zhou Y, Bick AG, et al. Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics. Immun Ageing 2022;19:23.
57. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012;44:1179-81.
58. Busque L, Mio R, Mattioli J, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 1996;88:59-65.
59. Mitchell E, Spencer Chapman M, Williams N, et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature 2022;606:343-50.
60. Florez MA, Tran BT, Wathan TK, DeGregori J, Pietras EM, King KY. Clonal hematopoiesis: mutation-specific adaptation to environmental change. Cell Stem Cell 2022;29:882-904.
61. Fabre MA, de Almeida JG, Fiorillo E, et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature 2022;606:335-42.
62. Matteini F, Mulaw MA, Florian MC. Aging of the hematopoietic stem cell niche: new tools to answer an old question. Front Immunol 2021;12:738204.
63. Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 2017;21:374-82.e4.
64. Wong TN, Miller CA, Jotte MRM, et al. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun 2018;9:455.
65. Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 2020;52:1219-26.
66. Hsu JI, Dayaram T, Tovy A, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 2018;23:700-13.e6.
67. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015;518:552-5.
68. Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 2010;6:309-22.
69. Young K, Eudy E, Bell R, et al. Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging. Cell Stem Cell 2021;28:1473-82.e7.
70. Doan PL, Himburg HA, Helms K, et al. Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nat Med 2013;19:295-304.
71. Itkin T, Ludin A, Gradus B, et al. FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation. Blood 2012;120:1843-55.
72. Cao X, Wu X, Frassica D, et al. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. Proc Natl Acad Sci USA 2011;108:1609-14.
73. Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche. Nat Rev Mol Cell Biol 2019;20:303-20.
74. Tikhonova AN, Dolgalev I, Hu H, et al. The bone marrow microenvironment at single-cell resolution. Nature 2019;569:222-8.
75. Garrett-Bakelman FE, Darshi M, Green SJ, et al. The NASA twins study: a multidimensional analysis of a year-long human spaceflight. Science 2019;364:eaau8650.
76. Mencia-Trinchant N, MacKay MJ, Chin C, et al. Clonal hematopoiesis before, during, and after human spaceflight. Cell Rep 2020;33:108458.
77. Brojakowska A, Kour A, Thel MC, et al. Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts. Commun Biol 2022;5:828.
78. Meisel M, Hinterleitner R, Pacis A, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 2018;557:580-4.
79. Cai Z, Kotzin JJ, Ramdas B, et al. Inhibition of Inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell 2018;23:833-49.e5.
80. Abegunde SO, Buckstein R, Wells RA, Rauh MJ. An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis. Exp Hematol 2018;59:60-5.
81. Zeng H, He H, Guo L, et al. Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies. Cancer Lett 2019;467:1-8.
82. Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling. Blood 2023;141:886-903.
83. Liao M, Chen R, Yang Y, et al. Aging-elevated inflammation promotes DNMT3A R878H-driven clonal hematopoiesis. Acta Pharm Sin B 2022;12:678-91.
84. Hormaechea-Agulla D, Matatall KA, Le DT, et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling. Cell Stem Cell 2021;28:1428-42.e6.
85. Heyde A, Rohde D, McAlpine CS, et al. Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell 2021;184:1348-61.e22.
86. Avagyan S, Henninger JE, Mannherz WP, et al. Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science 2021;374:768-72.
87. Ko M, Bandukwala HS, An J, et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011;108:14566-71.
88. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011;118:4509-18.
89. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011;20:11-24.
90. Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015;525:389-93.
91. Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res 2018;123:335-41.
92. Bick AG, Weinstock JS, Nandakumar SK, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature 2020;586:763-8.
93. Svensson EC, Madar A, Campbell CD, et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol 2022;7:521-8.
95. Sánchez-Cabo F, Fuster JJ. Clonal haematopoiesis and atherosclerosis: a chicken or egg question? Nat Rev Cardiol 2021;18:463-4.
96. Fuster JJ, Zuriaga MA, Zorita V, et al. TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep 2020;33:108326.
97. Jeong M, Park HJ, Celik H, et al. Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo. Cell Rep 2018;23:1-10.
98. Rauch PJ, Silver AJ, Gopakumar J, et al. Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and convergent macrophage phenotypes in mice. Blood 2018;132:745.
99. Zhang CR, Ostrander EL, Kukhar O, et al. Txnip enhances fitness of Dnmt3a-mutant hematopoietic stem cells via p21. Blood Cancer Discov 2022;3:220-39.
100. Oh J, Lee YD, Wagers AJ. Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat Med 2014;20:870-80.
101. Geiger H, de Haan G, Florian MC. The ageing haematopoietic stem cell compartment. Nat Rev Immunol 2013;13:376-89.
102. Amorim JA, Coppotelli G, Rolo AP, Palmeira CM, Ross JM, Sinclair DA. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol 2022;18:243-58.
103. Itokawa N, Oshima M, Koide S, et al. Epigenetic traits inscribed in chromatin accessibility in aged hematopoietic stem cells. Nat Commun 2022;13:2691.
104. Li X, Li C, Zhang W, Wang Y, Qian P, Huang H. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct Target Ther 2023;8:239.
105. Ho YH, Méndez-Ferrer S. Microenvironmental contributions to hematopoietic stem cell aging. Haematologica 2020;105:38-46.
106. Cobo I, Tanaka TN, Chandra Mangalhara K, et al. DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages. Immunity 2022;55:1386-401.e10.
107. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
108. Nakamura-Ishizu A, Ito K, Suda T. Hematopoietic stem cell metabolism during development and aging. Dev Cell 2020;54:239-55.
109. Bowers E, Singer K. Obesity-induced inflammation: the impact of the hematopoietic stem cell niche. JCI Insight 2021;6:145295.
110. Benova A, Tencerova M. Obesity-induced changes in bone marrow homeostasis. Front Endocrinol 2020;11:294.
111. Kim MJ, Song H, Koh Y, et al. Clonal hematopoiesis as a novel risk factor for type 2 diabetes mellitus in patients with hypercholesterolemia. Front Public Health 2023;11:1181879.
112. Tobias DK, Manning AK, Wessel J, et al. Clonal hematopoiesis of indeterminate potential (CHIP) and incident type 2 diabetes risk. Diabetes Care 2023;46:1978-85.
113. Andersson-Assarsson JC, van Deuren RC, Kristensson FM, et al. Evolution of age-related mutation-driven clonal haematopoiesis over 20 years is associated with metabolic dysfunction in obesity. EBioMedicine 2023;92:104621.
114. Bhattacharya R, Zekavat SM, Uddin MM, et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol 2021;6:1069-77.
115. Haring B, Reiner AP, Liu J, et al. Healthy lifestyle and clonal hematopoiesis of indeterminate potential: results from the women’s health initiative. J Am Heart Assoc 2021;10:e018789.
116. Zioni N, Bercovich AA, Chapal-Ilani N, et al. Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis. Nat Commun 2023;14:2070.
117. Ambrosi TH, Scialdone A, Graja A, et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell 2017;20:771-84.e6.
118. Verovskaya EV, Dellorusso PV, Passegué E. Losing sense of self and surroundings: hematopoietic stem cell aging and leukemic transformation. Trends Mol Med 2019;25:494-515.
119. Dawoud AAZ, Tapper WJ, Cross NCP. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia 2020;34:2660-72.
120. Chen J, Nie D, Wang X, et al. Enriched clonal hematopoiesis in seniors with dietary vitamin C inadequacy. Clin Nutr ESPEN 2021;46:179-84.
121. Nakao T, Bick AG, Taub MA, et al. Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Sci Adv 2022;8:eabl6579.
